The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Statins Are Underused in Women With NAFLD After Cardiovascular Events Compared With Matched Control Subjects
Clin Gastroenterol Hepatol. 2023 May;21(5):1359-1361.e2. doi: 10.1016/j.cgh.2022.03.020.Epub 2022 Mar 24.
1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Electronic address: ying.shang@ki.se.
2Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine, Stockholm, Karolinska Institutet, Stockholm, Sweden.
Abstract
Patients with nonalcoholic fatty liver disease (NAFLD) often have hyperlipidemia and are at a higher risk of cardiovascular disease (CVD).1 As first-line lipid-lowering drugs, statins are widely used for primary and secondary CVD prevention.2 However, there have been concerns about statins underprescription for patients with NAFLD because of fear of hepatoxicity.3 We aimed to describe and compare the pattern of statins use before and after CVD events in patients with NAFLD with the general population.
Stay Informed!
